跳至主要内容
临床试验/NCT02700191
NCT02700191撤回不适用

Cardiovascular Diagnosis Using µ-Cor - an Interventional Pilot Trial

Kyma Medical Technologies0 个研究点开始时间: 2016年5月4日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
主要终点
composite of all-cause death or hospitalizations due to heart failure in the Interventional arm compared to the Control arm.

研究概览

简要总结

Subjects that are being treated at the Congestive Heart Failure clinic in Nazareth will be given the µ-Cor system to be added to their standard care, and randomized 1:1 to an interventional arm or a control arm.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
Single (Participant)

入排标准

年龄范围
20 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men or women 20-90 years old.
  • New York Heart Association (NYHA) class III-IV heart failure
  • Followed by the Congestive Heart Failure (CHF) clinic in Nazareth
  • Left ventricular ejection fraction <35%
  • Requiring treatment with >40mg/day of furosemide* orally or with repeated bolus or intravenous infusion of furosemide* (*or equivalent bumetanide or torasemide).

排除标准

  • Pregnancy
  • Subjects who have received a heart transplant.
  • Subjects who are unable or unwilling to follow the study requirements.
  • Patients with allergies or skin sensitivities to electrode hydrogel and/or acrylic based adhesive.
  • Patients with skin breakdown in areas on the chest where device and electrode placement is required

结局指标

主要结局

composite of all-cause death or hospitalizations due to heart failure in the Interventional arm compared to the Control arm.

时间窗: 30 days to 3 months

次要结局

未报告次要终点

研究者

发起方
Kyma Medical Technologies
申办方类型
Industry
责任方
Sponsor

相似试验